Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOXR1030 CAR-GPC3 T cells in GPC3-positive solid tumors
NCT05120271Phase 2Active, not recruiting
- Sponsor
- SOTIO Biotech
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of BOXR1030 in hepatocellular carcinoma (HCC), lung squamous cell carcinoma (LSCC), Merkel cell carcinoma (MCC) and 1 more, sponsored by SOTIO Biotech. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
BOXR1030
03
Conditions
hepatocellular carcinoma (HCC)lung squamous cell carcinoma (LSCC)Merkel cell carcinoma (MCC)myxoid round cell liposarcoma (MRCLPS)
Beyond the preview
Go deeper on NCT05120271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120271.